FIELD: medicine.
SUBSTANCE: inventions group relates to medicine, namely to hepatology, and discloses the use of a compound of chemical formula 1 for the treatment or prevention of non-alcoholic steatohepatitis and liver fibrosis.
EFFECT: reducing the content of lipids in liver tissue, providing a therapeutic effect on inflammation of the liver tissue, as well as inhibiting liver tissue fibrosis when used to treat or prevent non-alcoholic steatohepatitis.
Formula 1
3 cl, 6 dwg, 5 ex
| Title |
Year |
Author |
Number |
| COMPOSITION FOR PREVENTING OR TREATING GASTROINTESTINAL DISORDERS CONTAINING S-ALLYL-L-CYSTEIN AS ACTIVE INGREDIENT |
2010 |
- Kim Son Peh
- Kim Kvan Son
- Kim Von Peh
- Kvak Vie Chon
- Pan Son Khe
|
RU2533268C2 |
| COMPOSITION FOR PREVENTING OR TREATING FATTY LIVER DISEASES |
2015 |
- Kim Soon Kha
- Kim Khioung Dzin
- Park Kheui Sul
- Akhn Seo Khiun
- Shong Min Kho
- Chung Khio Kiun
|
RU2664696C2 |
| PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF HEPATITIS, LIVER FIBROSIS AND LIVER CIRRHOSIS, INCLUDING FUSION PROTEINS |
2017 |
- Hong, Han Na
- Kim, Jun Hwan
- Choi, Hyun Ho
- Kim, Dohoon
- Kim, Taewang
- Oh, Se Woong
- Song, Moo Young
- Kim, Jong Gyun
|
RU2795548C2 |
| NALMEFEN, NALTREXONE OR DERIVATIVES THEREOF FOR USE IN TREATING (NON)-ALCOHOLIC STEATOHEPATITIS OR NON-ALCOHOLIC FATTY LIVER DISEASE |
2017 |
- Wu, Edwin, Sc
- Chiu, Peter, J.S.
- Hsu, May, Mei-Chi
|
RU2717677C1 |
| USE OF PEGYLATED RECOMBINANT CHIMERIC MOUSE FIBROBLAST-21 GROWTH FACTOR OR ITS PHARMACEUTICALLY ACCEPTABLE SALT IN COMPOSITION OF DRUGS FOR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS |
2018 |
- Li, Jian
- Han, Jun
- Ma, Xiaohui
- Tai, Ping
- Wang, Genbei
- Cao, Xiaodan
- Huang, Ruijing
- Jin, Yongjie
- Li, Jing
- Chen, Chen
- Jia, Guoyong
- Wang, Yuanyuan
|
RU2785582C2 |
| COMPOSITION AND METHOD OF PREVENTION, REMOVAL OF SYMPTOMS OR THERAPEUTIC EFFECT ON LIVER DAMAGE |
2020 |
- Ko, Gwang Pyo
- Kim, Won
- You, Hyun Ju
- Lee, Giljae
- Cho, Po-Ram
|
RU2810601C2 |
| NOVEL PROTEIN CONJUGATE AND USE THEREOF FOR PREVENTING OR TREATING NON-ALCOHOLIC STEATOHEPATITIS, OBESITY AND DIABETES |
2021 |
- Kim, Yunki
- Kim, Minsun
- Kim, Ryuryun
- Choi, Jaeyoung
- Yim, Yeseal
- Shim, Myungbo
- Han, Daye
- Im, Daeseong
- Park, Sungjin
|
RU2822001C1 |
| THERAPEUTIC AGENT FOR LIVER DISEASES |
2018 |
- Moon, Sung Hwan
- Lee, Soo Jin
- Lee, Sung Chan
- Bae, Yun Soo
|
RU2723686C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING 1,2-DITHIOL-THIONE DERIVATIVE FOR PREVENTING OR TREATING DISEASES MEDIATED BY HIGH LXR-ALPHA EXPRESSION |
2009 |
- Kim San Gon
- Ki Sun Khvan
- Khvan Son Khvan
|
RU2491065C2 |
| APPLICATION OF CB1 RECEPTOR ANTAGONISTS FOR PREPARATION OF COMPOSITION APPLICABLE FOR TREATMENT OF HEPATIC DISEASES |
2005 |
- Lotershtajn Sofi
- Mallat Arian
- Grenar Paskal'
- Zhul'En Boris
- Tran Van Njuen Zhan
|
RU2402328C2 |
